What is a Minimum Viable Product?
A Minimum Viable Product (MVP) is the fastest path from idea to market. By focusing only on core functionality, you can validate your business concept, test actual market demand, and gather crucial user feedback—all without draining your budget or wasting months on unproven features.
Phase 1 - Problem Identification (The "Why")
Clearly define and validate a specific, high-pain challenge faced by a well-defined target audience.
Before building anything, you conduct interviews and research to ensure the problem is real, frequent, and severe enough that people are actively looking for a solution. This phase confirms market demand.
Phase 2 - Problem Solution Fit (The "What")
Proving that your proposed MVP feature set directly and effectively solves the identified problem for early adopters with a prototype/mockup.
In short: Problem Identification ensures you are chasing the right pain, Problem-Solution Fit ensures your MVP actually fixes it, and Product-Market Fit ensures a large enough audience cares.
Phase 3 - Pilot Sites (The "Where" and "How")
Deploying and testing the MVP in controlled, real-world environments to validate real-time functionality and gather direct user feedback.
Key Objectives
- Workflow Integration: Validate seamless data intake from cross-platform edge devices and ensure data privacy compliance.
- User Feedback & Iteration: Collect real-time insights from clinicians, specialists, and participants to refine features.
- Impact Measurement: Measure key metrics such as reduced response times, improved diagnostic efficiency, and enhanced care coordination.
Executive / Leadership Summary
The doctoral researcher overseeing all three phases of this MVP brings over 20 years of firsthand experience navigating senior living, memory care, and assisted living systems—spanning all Global Deterioration Scale (GDS) stages through end-of-life care. This domain depth is combined with a proven track record of deploying large-scale enterprise technology. His specialized research focus addresses Mild Cognitive Impairment (MCI), early and clinical stages of dementia, and Alzheimer's disease.
Additionally, he previously managed an LG Electronics - Hospitality Solutions and Amazon Web Services (AWS) cloud large-scale MVP technology initiative that successfully deployed across 2,000+ commercial sites in the United States and currently serves over 50 million travelers annually.
What is a Proof-of-Concept?
In the product development lifecycle, a Proof-of-Concept (PoC) is an internal, small-scale test designed to validate whether a core technology, algorithm, or technical approach is feasibly possible before committing significant capital to an MVP build.
Rule of Thumb - Build a PoC to prove the technology. Build a Prototype to refine the user experience. Launch an MVP to validate the business model. The trajectory following an MVP moves through three distinct phases: Product-Market Fit (PMF), the Minimum Marketable Product (MMP), and the Scalable Commercial Product.
GRANT APPLICATIONS
To accelerate the development, clinical validation, and commercialization of AccelPath NeuroSystem, we are executing a multi-track funding strategy across state and federal research initiatives. This multi-vehicle model optimizes non-dilutive capital while building key institutional partnerships.
Aggregated Maximum: $10M +
- Start Stage: Aimed at pre-funded or bootstrapped Minimum Viable Products (MVPs), this stage offers initial validation with $2,000 in Google Cloud credits.
- Scale Stage: Geared toward startups that have secured post-seed funding or are accelerator-supported. This stage provides substantial infrastructure and support, including up to $100,000 to $200,000 in cloud credits and technical architecture reviews with Google engineers specializing in Gemini AI integration.
RESEARCH FINDINGS
What is Cognitive Speed Training?
“This study shows that simple brain training, done for just weeks, may help people stay mentally healthy for years longer,” said NIH Director Jay Bhattacharya, M.D., Ph.D. “That’s a powerful idea — that practical, affordable tools could help delay dementia and help older adults keep their independence and quality of life.”
"Your risk of dementia goes up starting at age 65."
"Dementia is not a single disease, but refers to brain changes that result in progressive loss of memory and impaired cognition. There are different types, including vascular dementia, which is often caused by strokes, and Alzheimer’s disease dementia, the most common and well-known."
"Alzheimer’s dementia in America continues to rise, with an estimated 7.4 million affected."
"Alzheimer’s dementia in America continues to rise, with an estimated 7.4 million affected."
"Nearly nine in 10 U.S. adults (88%) say maintaining brain health as they age is very important, and 99% say it is at least as important as physical health."
"Yet only 9% say they know a lot about how to maintain their brain health."
What is the DPRIT $3 billion fund?
"Alzheimer’s dementia in America continues to rise, with an estimated 7.4 million affected."
Dementia Prevention and Research Institute of Texas (DPRIT) is a new Texas state institute.
"Modeled after the successful Cancer Prevention and Research Institute of Texas (CPRIT), DPRIT will drive scientific breakthroughs, attract world-class researchers, and create thousands of jobs across the state. With its robust academic and medical infrastructure, Texas is uniquely positioned to set the gold standard for dementia innovation and impact."
What is Mild Cognitive Impairment?
"Mild Cognitive Impairment – an early stage of dementia – is widely underdiagnosed in people 65 and older."
"People, particularly those in their 60s and beyond, as well as their families and friends, need to be vigilant about cognitive decline."
What is the "golden age" of Alzheimer's research?
"This progress can’t come quickly enough. In 2017, 5.5 million people in the U.S. were living with the disease. Today, that number has ballooned to an estimated 7.4 million."
"This therapeutic platform has transformative potential to treat a vast range of neurological disorders."
"Some brains seem to defy Alzheimer's. Even when the disease's telltale plaques and tangles are present, certain individuals remain mentally sharp well into old age."
"Undiagnosed: More than 7 million Americans unaware they have mild cognitive impairment"
An estimated 7.4 million Americans aged 65 and older are living with clinical Alzheimer’s dementia in 2026.
About 1 in 9 people (11%) aged 65 and older has clinical Alzheimer’s dementia.
The percentage of people with clinical Alzheimer’s dementia increases with age: for example, 5.2% of people aged 65 to 74 and 35.8% of people aged 85 and older have clinical Alzheimer’s dementia. LEARN MORE